Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 4

  • 4

  • 3

  • 2

  • 2

  • 2

  • 1

  • 1

  • 1

  • 1

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Quantifying Risk and Resilience (R2) among Patients with Bladder Cancer: A Novel Personalized, Comprehensive Risk Stratification Program

Funder: Bladder Cancer Advocacy Network

Funding period
USD 50 K
Funding amount
Abstract
Background: Guidelines advocate for including a Comprehensive Geriatric Assessment (CGA) in the evaluation of elderly bladder cancer (BC) patients. To date, CGAs have not been studied in clinical pHypotheses: Integrating a comprehensive Risk and Resilience (R2) assessment in shared decision-making for localized BC will decrease decisional conflict and anxiety/depression, while improving generic health-related quality of life (HRQOL) and satisfaction with cancer-care satisfaction at treatment selection. Additionally, the R2 assessment will alter physicians’ subjective risk assessment and decrease physician-reported decisional-conflict score (DCS). Aims: 1)To compare changes in patient-reported decisional conflict and health-related quality of life among localized BC patients who completed the R2 assessment with those undergoing the usual risk assessment.2)To test the impact of the R2 assessment on provider’s subjective assessment of a patient’s fitness for definitive treatment for BC and physician-reported DCS after treatment selection. Methodologies: We will perform a prospective observational cohort study. Following informed consent, patients will receive standard of care risk assessment for 3 months and will serve as controls. Following treatment selection, patients will complete the DCS, PHQ-4 (anxiety and depression), QLQ-C30 and QLQ-BLM30 (HRQOL), and satisfaction with cancer care assessments; physicians will complete the DCS and render a subjective assessment of patients’ fitness for treatment. Patients being seen in months 4-11 will receive the R2 assessment. Patients and physicians will complete the outcome surveys as per above. Patient and physician-reported outcome measures will be compared between usual care and intervention cohorts. Concordance between physician risk assessment with/without the R2 score will be measured. This project responds to the BCAN PSN knowledge gaps in decision-making before definitive treatment of muscle-invasive BC.

 
21
Projects
USD 10.9 M
Aggregated funding amount
USD 545 K
Average funding amount
Project list item
Platform Selection for Biomarker Directed Radiotherapy for Bladder Cancer

NIHR Evaluation Trials and Studies Coordinating Centre to Catharine West

USD 51,871
2020 - 2020
Project list item
Geriatric Conditions and Treatment Burden in Older Adults with Non-Muscle-Invasive Bladder Cancer and Their Caregivers

National Institute on Aging to TULLIKA GARG

USD 271,698
2019 - 2021
Project list item
Understanding the Burden and Impact of Financial Toxicity in Bladder Cancer: A Mixed Methods Study of 2 Diverse Patient Populations

Bladder Cancer Advocacy Network to Sumeet Kaur Bhanvadia, Siamak Daneshmand, Reginald Tucker-Seeley

USD 50,000
2019 - 2020
Project list item
New Drug and Technology Assessment in Bladder Cancer: Creation of a Novel Canadian Policy Model for Bladder Cancer

Canadian Institutes of Health Research to Girish Satish Kulkarni, Murray Dale Krahn, Shabbir Muhammad Husayn Alibhai, Peter Colin Black, Wassim Kassouf, Nathan Perlis, George Andrew Tomlinson, William Wai Lun Wong

USD 77,161
2018 - 2019
Project list item
Studying the Effect of PPARG Pathway Modulation on Tumor Immune Microenvironment in Muscle Invasive Bladder Cancer

Congressionally Directed Medical Research Programs to Shruti D Shah

USD 262,050
2017 - 2018
Project list item
Patient Empowerment through Engagement Research Training in Bladder Cancer PCOR (PEER)

Patient-Centered Outcomes Research Institute to Angela Smith

USD 247,524
2017 - 2018
Project list item
Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: A Translational Study of S1602

Congressionally Directed Medical Research Programs to Robert Svatek

USD 428,545
2016 - 2017
Project list item
Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: A Translational Study of S1602

Congressionally Directed Medical Research Programs to Joshua J Meeks

USD 661,890
2016 - 2017
Project list item
Investigation of Genetic and Immune Mechanisms of Response to BCG for Non-Muscle Invasive Bladder Cancer: A Translational Study of S1602

Congressionally Directed Medical Research Programs to David Mcconkey

USD 437,139
2016 - 2017
Project list item
Novel Approach to Facilitate Decisions in Patients w/ Muscle Invasive Bladder CA

National Cancer Institute to MICHAEL A DIEFENBACH, MATTHEW GALSKY

USD 449,777
2015 - 2018
Project list item
Understanding physician knowledge, attitudes, and behaviour: Towards improving utilization rates of peri-operative chemotherapy for bladder cancer

Canadian Cancer Society to Christopher Booth, Deborah Feldman-stewart, Simon French, William Mackillop, Robert Siemens

USD 88,927
2014 - 2016
Project list item
Urodynamics for Prostate Surgery Trial; Randomised Evaluation of Assessment Methods (UPSTREAM) for diagnosis and management of bladder outlet obstruction in men

NIHR Evaluation Trials and Studies Coordinating Centre to Marcus Drake

USD 2,960,082
2014 - 2018
Project list item
Development of a utility weighting function for the Bladder Utility Symptom Scale (BUSS-U)

Canadian Cancer Society to Girish Kulkarni, Murray Krahn, Shabbir Alibhai, Joseph Chin, Peter Chung, Antonio Finelli, Alexander Louie, Nathan Perlis, Srikala Sridhar, George Tomlinson, Eric Winquist

USD 245,511
2014 - 2017
Project list item
Bladder Cancer Patient Survey Network for Research Prioritization

Patient-Centered Outcomes Research Institute to Angela Smith

USD 121,237
2014 - 2015
Project list item
A New Analytical Paradigm to Predict and Prevent Bladder Toxicity from Pelvic Radiation Therapy

Canadian Institutes of Health Research to Tara Rosewall, Michael Milosevic

USD 102,413
2013 - 2015
Project list item
Developing and Validating the BUSS (Bladder Utility Symptom Scale)- A Disease-Specific Utility Instrument for Bladder Cancer Health-Related Quality of Life

Canadian Institutes of Health Research to Girish Satish Kulkarni, Murray Dale Krahn, Shabbir Muhammad Husayn Alibhai, Antonio Finelli, Nathan Perlis, Paul G. Ritvo

USD 254,278
2012 - 2015
Project list item
Urinary Diversion Among Bladder Cancer Survivors: Cost, Complications, and QOL

National Cancer Institute to CARMIT KURN MCMULLEN

USD 3,080,828
2012 - 2018
load more...